New Antivirals and Antiviral Resistance

  • Charles G. Prober
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 549)


The field of antiviral therapy is relatively new. Whereas the first antibiotics were available in the 1940s, the first antiviral agent (idoxuridine) was not licensed until the 1960s. Furthermore, the number of antiviral agents available to clinicians today pale in comparison to the number of antibacterial agents. Conceptually it has been easier to develop antibacterial agents than antivirals. Bacteria replicate independent of the host whereas viruses are intracellular pathogens that depend upon viable host cells for their survival. Thus, it has been feared that agents toxic to viruses would also be toxic to host cells, whereas drugs active against bacteria are less likely to be toxic. However, an increasing understanding of molecular virology, including the identification of viral specific enzymatic and metabolic pathways, has facilitated the development of an increasing range of antiviral agents. Currently available antivirals have activity against the herpes family of viruses, influenza A and B, respiratory syncytial virus, hepatitis B and C, human papillomaviruses, lassavirus, and retroviruses (Kimberlin and Prober, 2003). Table 3.1 lists the non-antiretroviral antiviral agents licensed in the United States and the viruses against which they are active.


Herpes Simplex Respiratory Syncytial Virus Antiviral Therapy Antiviral Agent Herpes Simplex Virus Infection 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Arvin, A.M. (2002). Antiviral therapy for varicella and herpes zoster. Semin. Pediatr. Infect. Dis. 13, 12–21.PubMedCrossRefGoogle Scholar
  2. Bacon, T.H., Levin, M.J., Leary, J.J., Sarisky, R.T., and Sutton, D. (2003). Herpes simplex virus resistance to acyclovir and penciclovir after two decades of antiviral therapy. Clin. Microbiol. Rev. 16, 114–128.PubMedCrossRefGoogle Scholar
  3. Ganem, D. and Prince, A.M. (2004). Hepatitis B virus infection—natural history and clinical consequences. N. Engl. J. Med. 350, 1118–1129.PubMedCrossRefGoogle Scholar
  4. Greenough, A. (2002). Respiratory syncytial virus infection: Clinical features, management, and prophylaxis. Curr. Opin. Pulm. Med. 8, 214–217.PubMedCrossRefGoogle Scholar
  5. Hamprecht, K., Eckle, T., Prix, L., Faul, C., Einsele, H., and Jahn, G. (2003). Ganciclovir-resistant cytomegalovirus disease after allogeneic stem cell transplantation: Pitfalls of phenotypic diagnosis by in vitro selection of an UL97 mutant strain. J. Infect. Dis. 187, 139–143.PubMedCrossRefGoogle Scholar
  6. Hayden, F.G. and Hay, A.J. (1992). Emergence and transmission of influenza A viruses resistant to amantadine and rimantadine. Curr. Top. Microbiol. Immunol. 176, 119–130.PubMedCrossRefGoogle Scholar
  7. Kimberlin, D.W., Crumpacker, C.S., Straus, S.E., Biron, K.K., Drew, W.L., Hayden, F.G. et al. (1995). Antiviral resistance in clinical practice. Antiviral Res. 26, 423–438.PubMedCrossRefGoogle Scholar
  8. Kimberlin, D.W. and Prober, C.G. (2003). Antiviral agents, In S.S. Long, L.J. Pickering, C.G. Prober (eds.) Principles and Practice of Pediatric Infectious Diseases. 2nd edn, Churchill Livingstone, Philadelphia, pp. 1527–1546.Google Scholar
  9. Kimberlin, D.W., Lin, C.Y., Sanchez, P.J., Demmler, G.J., Dankner, W., Shelton, M. et al. (2003). Effect of ganciclovir therapy on hearing in symptomatic congenital cytomegalovirus disease involving the central nervous system: A randomized, controlled trial. J. Pediatr. 143, 16–25.PubMedCrossRefGoogle Scholar
  10. Khare, M.D. and Sharland, M. (2001). Cytomegalovirus treatment options in immunocompromised patients. J. Clin. Virol. 26, 29–37.Google Scholar
  11. Monto, A.S. (2003). The role of antivirals in the control of influenza. Vaccine 21, 1796–1800.PubMedCrossRefGoogle Scholar
  12. Morfin, F. and Thouvenot, D. (2003). Herpes simplex virus resistance to antiviral drugs. J. Clin. Virol. 26, 29–37.PubMedCrossRefGoogle Scholar
  13. Prober, C.G. (2002). Antiviral therapy for influenza virus infections. Semin. Pediatr. Infect. Dis. 13, 31–39.PubMedCrossRefGoogle Scholar
  14. Report of the Committee on Infectious Diseases. (2003). 26th Edn. L.K. Pickering, ed. American Academy of Pediatrics, Elk Grove Village, IL.Google Scholar
  15. Schwarz, K.B. (2003). Pediatric issues in new therapies for hepatitis B and C. Curr. Gastroenterol. Rep. 5, 233–239.PubMedCrossRefGoogle Scholar
  16. Spruance, S.L., Stewart, J.C., Rowe, N.H., McKeough, M.B., Wenerstrom, G., and Freeman, D.J. (1990). Treatment of recurrent herpes simplex labialis with oral acyclovir. J. Infect. Dis. 161, 185–190.PubMedCrossRefGoogle Scholar
  17. Whitley, R.J. and Lakeman, F. (1995). Herpes simplex virus infections of the central nervous system: Therapeutic and diagnostic considerations. Clin. Infect. Dis. 20, 414–420.PubMedCrossRefGoogle Scholar
  18. Whitley, R.J., Kimberlin, D.W., and Roizman, B. (1998). Herpes simplex viruses. Clin. Infect. Dis. 26, 541–555.PubMedCrossRefGoogle Scholar

Copyright information

© Science+Business Media New York 2004

Authors and Affiliations

  • Charles G. Prober

There are no affiliations available

Personalised recommendations